Active Biotech Interim Report Q1 2026
EVENTS DURING THE FIRST QUARTER
- The US Patent Office (US PTO) granted a patent related to a pharmaceutical formulation of tasquinimod (January)
- Active Biotech receives positive feedback on its clinical study with tasquinimod in myelofibrosis (February 10)
EVENTS AFTER THE END OF THE PERIOD
- Annual Report 2025 Active Biotech AB (publ) published (April 1)
- Preclinical data with tasquinimod in myelodysplastic neoplasms published in HemaSphere (April 14)
- Active Biotech publishes results from the LION study on ocular absorption and distribution of laquinimod in the eye (April 20)
FINANCIAL SUMMARY
| SEK M | Jan-Mar | Full year | |
| 2026 | 2025 | 2025 | |
| Net sales | – | – | – |
| Operating profit/loss | -8.6 | -11.2 | -37.6 |
| Profit/loss after tax | -8.4 | -11.0 | -37.3 |
| Earnings per share (SEK) | -0.00 | -0.01 | -0.03 |
| Cash and cash equivalents (at close of period) | 53.3 | 26.2 | 65.1 |
The report is also available at www.activebiotech.com
The information was submitted, through the agency of the contact person below, for public disclosure on 2026-05-07 at 08:30 CEST.
Active Biotech AB (Corp.Reg.no. 556223-9227) / Scheelevägen 22, SE-223 63 Lund / +46 46 19 20 00